March Bio Starts Phase 2 Trial for Rare Blood Cancer

March Bio Starts Phase 2 Trial for Rare Blood Cancer

By Karen Roman March Biosciences said it started Phase 2 trial for MB-105, its CAR-T therapy for patients with relapsed or refractory CD5+ T-cell lymphoma. The test will take place at leading cancer centers across the country, with the first...

Nanox New Imaging System Receives FDA Clearance

Nanox New Imaging System Receives FDA Clearance

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its multi-source digital imaging system, Nanox.ARC X, received FDA 510(k) clearance for general use. The Nanox.ARC X has a simplified “plug and play” one-day installation feature and allows remote software upgrades,...

Input your search keywords and press Enter.